Immunic (NASDAQ:IMUX) Releases Earnings Results

Key Points

• Immunic reported a quarterly loss of $0.99 per share, missing analyst expectations of a $0.79 loss by $0.20.
• The company said its pivotal ENSURE-1 and ENSURE-2 multiple sclerosis trials remain on track for top-line results in December, and it expects its funding to last into late 2027.
• Shares fell $0.27 to $7.52 in Friday mid-day trading. Analyst views are mixed, though MarketBeat’s consensus rating is “Moderate Buy” with a $35.43 average price target.

Immunic (NASDAQ:IMUX - Get Free Report) posted its earnings results on Friday. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.79) by ($0.20), FiscalAI reports.

Immunic Stock Performance

Shares of IMUX stock traded down $0.27 during mid-day trading on Friday, hitting $7.52. The company's stock had a trading volume of 105,145 shares, compared to its average volume of 297,743. The company's fifty day simple moving average is $8.80 and its 200-day simple moving average is $11.51. Immunic has a 52 week low of $5.06 and a 52 week high of $17.43. The company has a market cap of $102.57 million, a PE ratio of -1.72 and a beta of 1.48.

Immunic News Summary

These are some of the IMUX news items that stood out recently:

• Positive Sentiment: The company said its pivotal ENSURE-1 and ENSURE-2 trials remain on track to report top-line results in December. It also expects its funding to last into late 2027, giving it runway beyond the upcoming readout. Article: Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027
• Neutral Sentiment: Immunic is preparing to start its Phase 3 PROTECT-MS trial for progressive MS, with first-patient enrollment expected in the first half of 2027. The company also announced leadership appointments intended to support regulatory and commercial readiness. Article: Immunic reports third-quarter 2026 financial results and provides corporate update
• Negative Sentiment: Zacks Research downgraded Immunic from “strong-buy” to “hold,” adding to near-term caution ahead of the trial results. Article: Zacks Research stock recommendations

Analyst Ratings Changes

Several research firms have recently issued reports on IMUX. Roth Capital reaffirmed a "buy" rating on shares of Immunic in a research note on Tuesday, September 1st. Ladenburg Thalmann & Co. Inc. raised Immunic to a "strong-buy" rating in a research report on Wednesday, July 29th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunic in a report on Wednesday, August 26th. Cantor Fitzgerald began coverage on Immunic in a research report on Friday, October 23rd. They issued an "overweight" rating on the stock. Finally, Zacks Research lowered Immunic from a "strong-buy" rating to a "hold" rating in a research report on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $35.43.

Immunic Company Profile

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company's research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.